Archiv
Archiv anzeigen:
bis


A New Endocrine Agent for ER+/HER2− Breast Cancer

William J. Gradishar, MD reviewing Hamilton EP et al. Clin Cancer Res 2018 Feb 13, Jordan VC. Clin Cancer Res 2018 Apr 19

The oral selective estrogen receptor degrader AZD9496 demonstrated activity in heavily pretreated patients.


Selective Internal Radiation vs. Sorafenib for Hepatocellular Carcinoma

David H. Ilson, MD, PhD reviewing Chow PKH et al. J Clin Oncol 2018 Jul 1

Intrahepatic radiation failed to improve survival but was associated with a higher response rate and fewer adverse events.


Pembrolizumab for ER+/HER2− Metastatic Breast Cancer

William J. Gradishar, MD reviewing Rugo HS et al. Clin Cancer Res 2018 Jun 15

The checkpoint inhibitor pembrolizumab provided a modest but durable response in heavily pretreated patients with PD-L1–positive tumors.


Can We Use Direct Oral Anticoagulant Agents to Treat Venous Thromboembolism in Patients with Cancer?

Daniel D. Dressler, MD, MSc, SFHM, FACP reviewing Young AM et al. J Clin Oncol 2018 Jul 10

Rivaroxaban was an effective alternative to low-molecular-weight heparin for managing VTE in many — but not all — patients with active cancer.


Acupuncture for Joint Pain Associated with Aromatase Inhibitors for Breast Cancer

Eleanor Bimla Schwarz, MD, MS reviewing Hershman DL et al. JAMA 2018 Jul 10

This nonpharmacologic intervention helped control joint pain.


Rivaroxaban vs. Warfarin for High-Risk Antiphospholipid Antibody Syndrome

David Green, MD, PhD reviewing Pengo V et al. Blood 2018 Jul 12

The trial was terminated early due to an excess of adverse events, including arterial thrombosis and major bleeding, with rivaroxaban.


Hemostatic Efficiency of Pathogen-Inactivated Platelets

David Green, MD, PhD reviewing van der Meer PF et al. Blood 2018 Jul

Bleeding episodes were more frequent with treated versus untreated platelets.


Percutaneous Ablation for Patients with Small Renal Cancers

Robert Dreicer, MD, MS, FACP, FASCO reviewing Talenfeld AD et al. Ann Intern Med 2018 Jun 26

Survival was slightly poorer with percutaneous ablation versus partial nephrectomy, but perioperative complications were significantly reduced.


Port Thrombosis in Cancer Patients

David Green, MD, PhD reviewing Decousus H et al. Blood 2018 Jul 6

Among outpatients with implanted ports, nearly 4% had catheter-related thrombosis, and 10% had venous thromboembolism.


Cabozantinib for Advanced Hepatocellular Cancer

David H. Ilson, MD, PhD reviewing Abou-Alfa GK et al. N Engl J Med 2018 Jul 5

Overall and progression-free survival were significantly improved with cabozantinib versus placebo.


Archiv
Seite von 72
Editorial Member Board Empfehlungen

PD Dr. med. Katja Zirlik

Hämatologie und internistische Onkologie
Tumorzentrum ZeTuP Chur

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

Beim nicht kleinzelligen Lungenkarzinom (NSCLC) ist die Immuntherapie bereits in allen Therapielinien zugelassen. Die immunhistochemische Bestimmung der PD-L1-Expression auf den Tumorzellen ist derzeit der am besten validierte prädiktive Biomarker für die Therapie mit Checkpoint-Inhibitoren. Die vorliegende Studie untersuchte bei 848 Patienten mit NSCLC, ob die Mutationslast («tumor mutational burden», TMB), mittels «next-generation sequencing» (NGS) bestimmt, einen weiteren Marker darstellt, der die Wirksamkeit der Immuntherapie vorhersagen kann. Eine höhere Mutationslast war assoziiert mit einer Verbesserung im Hinblick auf die Ansprechrate sowie die Ansprechdauer. NSCLC-Patienten mit einer hohen Mutationslast profitieren demnach mehr von einer Immuntherapie.

Kommentar weiterlesen

First-Line Lenvatinib vs. Sorafenib for Unresectable Hepatocellular Carcinoma

David H. Ilson, MD, PhD reviewing Kudo M et al. Lancet 2018 Feb 9, Reig M and Bruix J. Lancet 2018 Feb 9

Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.


Apalutamide for Castration-Resistant PSA-Only Prostate Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Smith MR et al. N Engl J Med 2018 Feb 8

Metastasis-free survival was significantly longer with apalutamide than with placebo.


Second-Line Olaparib for Gastric Cancer

David H. Ilson, MD, PhD reviewing Bang Y-J et al. Lancet Oncol 2017 Dec

Contrary to prior findings, adding olaparib to paclitaxel failed to improve survival in patients with disease progression following chemotherapy.


Predicting Response to Immunotherapy in Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Rizvi H et al. J Clin Oncol 2018 Jan 16

Assessment of tumor mutation burden using targeted next-generation sequencing may be predictive of benefit from PD-1 and PD-L1 inhibitors.


Prolonged Adjuvant Aromatase Inhibitor Treatment for Early Breast Cancer

William J. Gradishar, MD reviewing Blok EJ et al. J Natl Cancer Inst 2018 Jan 1, Goldvaser H et al. J Natl Cancer Inst 2018 Jan 1, Pohlmann PR and Isaacs C. J Natl Cancer Inst 2018 Jan 1

Outcomes were not superior with 5 versus 2.5 years of extended letrozole therapy.


Prognosis of Monoclonal Gammopathy of Undetermined Significance

David Green, MD, PhD reviewing Kyle RA et al. N Engl J Med 2018 Jan 18

Overall survival was significantly shorter among MGUS patients than among a matched control population in a long-term follow-up study.


Prognosis for BRCA-Mutated Breast Cancer

William J. Gradishar, MD reviewing Copson ER et al. Lancet Oncol 2018 Jan 11

Survival is similar between BRCA mutation carriers versus those with sporadic disease.


Electrical Field Therapy for Glioblastoma

Roy E. Strowd, MD reviewing Stupp R et al. JAMA 2017 Dec 19

Adding tumor-treating electrical-field therapy to maintenance temozolomide chemotherapy significantly improved survival in patients with newly diagnosed glioblastoma.


Atezolizumab for Advanced Urothelial Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Powles T et al. Lancet 2017 Dec 18, Massari F and Di Nunno V. Lancet 2017 Dec 18

Overall survival was not improved with the PD-L1 inhibitor atezolizumab versus chemotherapy in patients with highest PD-L1 expression.


Pembrolizumab for Cisplatin-Ineligible Patients with Advanced Urothelial Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Balar AV et al. Lancet Oncol 2017 Sep 26

First-line therapy demonstrated antitumor activity in a phase II study.